MedTrace Logo

Bendamustine and Bevacizumab for Advanced Cancers

NCT01152203 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2015-11-18

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable combination dose of bendamustine and bevacizumab that can be given to patients with advanced cancer. The safety of the drug combination will also be studied.

Conditions

Interventions

DRUG

Bendamustine

Starting dose of 70 mg/m\^2 by vein on Days 1 and 2 of a 28 day cycle

DRUG

Bevacizumab

10 mg/kg by vein on Days 1 \& 15 of every 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Apostolia M. Tsimberidou, MD, PhD · UT MD Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01152203 on ClinicalTrials.gov